SIEMENS HEALTHCARE DIAGNOSTICS, INC. ATELLICA IM ANTI-HEPATITIS B CORE TOTAL (HBCT); TEST, HEPATITIS B (B CORE, BE ANTIGEN, BE ANTIBODY, B CORE IGM)
|
Back to Search Results |
|
Model Number N/A |
Device Problem
False Negative Result (1225)
|
Patient Problem
No Clinical Signs, Symptoms or Conditions (4582)
|
Event Date 06/08/2023 |
Event Type
malfunction
|
Event Description
|
The customer reports observation of a nonreactive atellica im anti-hepatitis b core total (hbct) result which was discordant relative to alternate-method testing.Hbct kit lot 182 was in use at the time of the discordant observation.The customer is performing a comparison study wherein previously-tested patient samples are re-tested for correlation against a new method.During this comparison study, a sample was identified for which the initial hbct measurement was nonreactive (negative), but testing using atellica im hbct2 (new method) as well as an additional alternate method produced reactive (positive) results.The initial nonreactive hbct result was retrospectively identified as discordant and potentially falsely negative by comparison with the new test results.This 63-year-old male patient was undergoing hbv screening at the time due to increased levels of liver transaminases.There are no allegations of patient harm, changes in treatment, or delays of diagnosis in association with the observed discordance.
|
|
Manufacturer Narrative
|
A customer from outside the united states reported observation of a nonreactive atellica im anti-hepatitis b core total (hbct) result which was discordant relative to alternate-method testing.The assay's instructions for use (ifu) states the following, under limitations: "the performance of the assay has not been established for populations of immunocompromised or immunosuppressed patients." siemens is investigating.
|
|
Manufacturer Narrative
|
Mdr 1219913-2023-00202 was initially submitted on 2023-09-20.A customer from outside the united states reported observation of a nonreactive atellica im anti-hepatitis b core total (hbct) result which was discordant relative to alternate-method testing.Additional information, 2023-09-29: siemens has concluded the investigation.The hbct result was nonreactive (0.41 index, vs.Cutoff of 0.50 index).Atellica im hbct2 and an alternate-method hbct assay produced reactive (positive) results.The sample was also hbsag nonreactive and anti-hbs reactive indicating this patient has recovered from an earlier hepatitis b virus (hbv) infection.Reagent issues were ruled out, as quality control (qc) results were within appropriate ranges and no issues were identified for any other patient samples.As the sample was initially tested in (b)(6) 2023, instrument data are no longer available to permit evaluation of whether an instrument issue may have contributed to the event.It is noted that the architecture of the (alternate) hbct2 assay has been designed to improve sensitivity to anti-hbc igg, which is the predominant antibody class in patients that have recovered from a previous hbv infection.Based on the available information, the cause of the discordant result for this sample cannot be determined, but siemens cannot rule out an analyzer issue or an isolated anomalous result within normal assay performance.The customer is operational, and no product problem was identified.
|
|
Search Alerts/Recalls
|
|
|